← Product Code [LOO](/submissions/MI/subpart-d%E2%80%94serological-reagents/LOO) · K023483

# KALAZAR DETECT (K023483)

_Inbios Intl., Inc. · LOO · May 6, 2003 · Microbiology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LOO/K023483

## Device Facts

- **Applicant:** Inbios Intl., Inc.
- **Product Code:** [LOO](/submissions/MI/subpart-d%E2%80%94serological-reagents/LOO.md)
- **Decision Date:** May 6, 2003
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 866.3870
- **Device Class:** Class 1
- **Review Panel:** Microbiology

## Indications for Use

The Kalazar Detect™ Test is a rapid immuno-chromatographic strip assay for the qualitative detection of antibodies to members of L. donovani complex in human serum. This test is intended for laboratory or professional in vitro diagnostic use only.

## Device Story

Kalazar Detect™ is a rapid immuno-chromatographic strip assay; detects antibodies to L. donovani complex in human serum. Used in laboratory or professional clinical settings; performed by trained personnel. Input: human serum sample. Principle: lateral flow immunoassay. Output: qualitative visual result on test strip. Assists clinicians in diagnosing visceral leishmaniasis.

## Clinical Evidence

No clinical data provided in the document.

## Technological Characteristics

Immuno-chromatographic strip assay; lateral flow technology. Qualitative visual readout. In vitro diagnostic reagent.

## Regulatory Identification

Trypanosoma spp. serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to Trypanosoma spp. in serum. The identification aids in the diagnosis of trypanosomiasis, a disease caused by parasitic protozoans belonging to the genus Trypanosoma. Trypanosomiasis in adults is a chronic disease characterized by fever, chills, headache, and vomiting. Central nervous system involvement produces typical sleeping sickness syndrome: physical exhaustion, inability to eat, tissue wasting, and eventual death. Chagas disease, an acute form of trypanosomiasis in children, most seriously affects the central nervous system and heart muscle.

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

## DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure, with three curved lines representing its wings or body. The bird is positioned within a circular border, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES (USA)" is arranged around the upper portion of the circle.

MAY 0 6 2003

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ms. Estela I. Raychaudhuri President/CEO InBios International, Inc. 562 1st Ave. S. Suite 600 Seattle, WA 98104

Re: k023483

Trade/Device Name: Kalazar Detect™ Rapid Test for the Detection of Visceral Leishmaniasis Regulation Number: 21 CFR 866.3870 Regulation Name: Trypanosoma Spp. Serological Reagents Regulatory Class: Class I Product Code: LOO Dated: April 1, 2003 Received: April 2, 2003

Dear Ms. Raychaudhuri:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21. Code of Federal Regulations (CFR). Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements. including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820).

{1}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

510(k) NUMBER (if Known): KNOWN): KOSZ 483

device name: Kalazar detect™ Rapid TEST For The detection OF VISCERAL LEISHMANIASIS

INDICATION FOR USE:

The Kalazar Detect™ Test is a rapid immuno-chromatographic strip assay for the qualitative detection of antibodies to members of L. donovani complex in human serum. This test is intended for laboratory or professional in vitro diagnostic use only.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation

| Prescription Use | <div>or</div> | Over-the-Counter |
|------------------|---------------|------------------|
|------------------|---------------|------------------|

Freddie Poole.

(Division Sign-Off) Division of Clinical Laboratory Devices < 0 . 510(k) Number -

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LOO/K023483](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/LOO/K023483)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com